Clinical relevance of resistance to antifungals

International Journal of Antimicrobial Agents

Volumn 32, Issue SUPPL. 2, 2008, Pages

  Rodriguez Tudela, Juan Luis ^a   Alcazar Fuoli, Laura ^a   Cuesta, Isabel ^a   Alastruey Izquierdo, Ana ^a   Monzon, Araceli ^a   Mellado, Emilia ^a   Cuenca Estrella, Manuel ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Antifungal sensitivity tests; Drug resistance; fungal; Minimum inhibitory concentration

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; DRUG RESPONSE; DRUG SENSITIVITY; GENE MUTATION; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; STRAIN IDENTIFICATION; THRUSH;

ANTIFUNGAL AGENTS; DRUG RESISTANCE, FUNGAL; EUROPE; FUNGI; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOSES; UNITED STATES;

EID: 55649097499     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(08)70010-4     Document Type: Article

References (25)

1. Lass F., Cuenca-Estrella M., Denning D.W., and Rodriguez-Tudela J.L. Antifungal susceptibility testing in Aspergillus spp. according to EUCAST methodology. Med Mycology 44 Suppl (2006) S319-S325
2. Rodriguez-Tudela J.L., Arendrup M.C., Barchiesi F., Bille J., Chryssanthou E., Cuenca-Estrella M., et al. EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect 14 (2008) 398-405
3. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M38-A. Wayne, PA: National Committee for Clinical Laboratory Standards; 2002.
4. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A2. Wayne, PA: National Committee for Clinical Laboratory Standards; 2002.
5. Pfaller M.A., Diekema D.J., and Sheehan D.J. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 19 (2006) 435-447
6. Rex J.H., Pfaller M.A., Galgiani J.N., Bartlett M.S., Espinel-Ingroff A., Ghannoum M.A., et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 24 (1997) 235-247
7. Tudela J.L.R., Donnelly J.P., Arendrup M.C., Arikan S., Barchiesi F., Bille J., et al. EUCAST technical note on fluconazole. Clin Microbiol Infect 14 (2008) 193-195
8. Cuenca-Estrella M., Ruiz-Diez B., Martinez-Suarez J.V., Monzon A., and Rodriguez-Tudela J.L. Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother 43 (1999) 149-151
9. Cuenca-Estrella M., Gomez-Lopez A., Mellado E., Buitrago M.J., Monzon A., and Rodriguez-Tudela J.L. Scopulariopsis brevicaulis, a fungal pathogen resistant to broad-spectrum antifungal agents. Antimicrob Agents Chemother 47 (2003) 2339-2341
10. Rodriguez-Tudela J.L., Alcazar-Fuoli L., Alastruey-Izquierdo A., Monzon A., Mellado E., and Cuenca-Estrella M. Time of incubation for antifungal susceptibility testing of Aspergillus fumigatus: Can MIC values be obtained at 24 hours?. Antimicrob Agents Chemother 51 (2007) 4502-4504
11. Diaz-Guerra T.M., Mellado E., Cuenca-Estrella M., and Rodriguez-Tudela J.L. A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 47 (2003) 1120-1124
12. Mellado E., Garcia-Effron G., Alcazar-Fuoli L., Cuenca-Estrella M., and Rodriguez-Tudela J.L. Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob Agents Chemother 48 (2004) 2747-2750
13. Mellado E., Garcia-Effron G., Alcazar-Fuoli L., Melchers W.J.G., Verweij P.E., Cuenca-Estrella M., et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother 51 (2007) 1897-1904
14. Sanglard D., and Odds F.C. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2 (2002) 73-85
15. Pfaller M.A., Diekema D.J., Rex J.H., Espinel-Ingroff A., Johnson E.M., Andes D., et al. Correlation of MIC with outcome for Candida species tested against voriconazole: Analysis and proposal for interpretive breakpoints. J Clin Microbiol 44 (2006) 819-826
16. Rodriguez-Tudela J.L., Almirante B., Rodriguez-Pardo D., Laguna F., Donnelly J.P., Mouton J.W., et al. Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. Antimicrob Agents Chemotherapy 51 (2007) 3599-3604
17. Almirante B., Rodriguez D., Park B.J., Cuenca-Estrella M., Planes A.M., Almela M., et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 43 (2005) 1829-1835
18. Fuhrmann V., Schenk P., Jaeger W., Miksits M., Kneidinger N., Warszawska J., et al. Pharmacokinetics of voriconazole during continuous venovenous haemodiafiltration. J Antimicrob Chemother 60 (2007) 1085-1090
19. Pascual A., Calandra T., Bolay S., Buclin T., Bille J., and Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 46 (2008) 201-211
20. EUCAST European Committee on Antibiotic Susceptibility Testing. © European Society of Clinical Microbiology and Infectious Diseases. http://www.escmid.org/sites/index_f.aspx?par=2.4 [accessed 13 August 2008].
21. Cuenca-Estrella M., Gomez-Lopez A., Mellado E., Buitrago M.J., Monzon A., and Rodriguez-Tudela J.L. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 50 (2006) 917-921
22. Lass-Florl C., Griff K., Mayr A., Petzer A., Gastl G., Bonatti H., et al. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br J Haematol 131 (2005) 201-207
23. Alastruey-Izquierdo A., Cuenca-Estrella M., Monzon A., Mellado E., and Rodriguez-Tudela J.L. Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. J Antimicrob Chemother 61 (2008) 805-809
24. Berenguer J., Rodriguez-Tudela J.L., Richard C., Alvarez M., Sanz M.A., Gaztelurrutia L., et al. Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Scedosporium Prolificans Spanish Study Group. Medicine (Baltimore) 76 (1997) 256-265
25. Guarro J., Kantarcioglu A.S., Horré R., Rodriguez-Tudela J.L., Estrella M.C., et al. Scedosporium apiospermum: changing clinical spectrum of a therapy-refractory opportunist. Med Mycology 44 (2006) 295-327